Floatz logo

Liposomal Cytarabine-Daunorubicin Cpx-351

Acute Myeloblastic Leukemia With Maturation

Rondeep BrarunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acute Myeloblastic Leukemia With Maturation cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Northwestern University
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB
Idarubicine
Bruno C. Medeiros
Phase 3BBB

View all 49 →

Same molecule, other indications

Liposomal Cytarabine-Daunorubicin Cpx-351 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
acute erythroid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
acute megakaryoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →